{"name":"Skye Bioscience","slug":"skye","ticker":"SKYE","exchange":"NASDAQ","domain":"skyebioscience.com","description":"Skye Bioscience is a biopharmaceutical company focused on developing novel therapeutics for the treatment of obesity and ophthalmology disorders. The company's lead product candidate, ZT-01, is a proprietary, non-psychedelic cannabinoid receptor agonist being developed for the treatment of glaucoma. Skye Bioscience is a relatively small company with limited market presence, but its pipeline holds promise for future growth.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Punit Dhillon","sector":"Obesity / Ophthalmology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$320M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":6011805,"netIncome":-55924814,"cash":28313633,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"earnings","headline":"Skye Bioscience Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Skye Bioscience reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $13.4 million and $53.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Skye Bioscience Announces Collaboration with University of California, San Diego to Develop Novel Therapeutics for Ophthalmic Disorders","summary":"Skye Bioscience entered into a collaboration with the University of California, San Diego to develop novel therapeutics for ophthalmic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNRDY1bFdJeFR3bjluRGtPeHAzYzhGMFFidnhSSTlOMTBSZHBZY3oxSjd5a3VlUl9SRWtIMWU5RzQzOFpGZFE2c1BiMGRsR3VhQktReUhlWjBUZmtkODJuN3pSZEtmSEUxV0pFY3hQX2JiUnc4N0F0Z2NYNkJ3dFFZdUtmM1k1QjhkUGJ6dTNjb2l2VGk3cGZwNXRiVEdnbjNTakpvQkFGZHJVLXlEU2lCVGpETTB3ZEZUeGlXY0lZeHZiWlRpaGc5QU5yQ2FxMVJDcVhsb3JpWlVPa01GNDRYbmlDWlV2dFpwZWZTWFM2TkR1TWxRU2J1WkVVOGZhRHY4blMxSGpXVEswQWRLenR4ZnljNm0zeVlBS0M4VnlDNlhTY28?oc=5","date":"2026-01-05","type":"deal","source":"PR Newswire","summary":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PR Newswire","headline":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNWjloRUNwT09LTGZFeXJtM2ExcVR2dXE4c1pXU3N0SHBrTUlFbENnTFVNTkFIOU15MHNINWo4RWZCVHR4S2lQTlBlWHMtMDVkMlZ1UmpheVJ4b0VVWEVBajNRZHpWNnZCT3pRWkt2b0RVX1BHUmRFMnYwakZmcUZYMzhyS042amNVWHRzVk1qSmw0UjRiZ2tTZGl0di03T2M4UHNZdTh4RmROVndYRzZfWXpiUQ?oc=5","date":"2026-01-05","type":"deal","source":"Contract Pharma","summary":"Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma","headline":"Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPaC1SSi1STlI4WlBuOFZ5dEJWNl9HRXhpS0E3dWFWdGVqMldhZVp4ZFIyUnVnYzJqSTFIYmF4LS0zbXJzRG8xakQ2NVJsRmtrTC10aHFhcmV4ck9PUk5Fakg3M19TRFlUaDFPa0F4eGlYVWVCY3AxZ0VCNlpPQko3NG84UDNSMkpwdEl4eW9fM2gyRkkyajZleQ?oc=5","date":"2025-10-06","type":"trial","source":"BioPharma Dive","summary":"Skye shares crash as obesity drug falls short in key study - BioPharma Dive","headline":"Skye shares crash as obesity drug falls short in key study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQV3ZXU3VIRkhnS243XzVqVUd2S3drMkVNOFNVaVBvbnVDRWhpOW1iSHUtTkluRFZQUldRVnN6WVoxd0poUnJ3dWxScmNFdUxBdDdrbFk0dHN6VkJBVzFDWGtBVUw1RkFpS3J3MUJlY0hJTnVyRDM5VVNvNGJEUEFsMlR6TVViRW12S1ktb0tDakowWU5DTGwzMXRPcFdEZ1NtNVhZR1VuUFhUR1VUelhhWg?oc=5","date":"2025-10-06","type":"trial","source":"Fierce Biotech","summary":"Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study - Fierce Biotech","headline":"Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTGo4azN6U19waF9fajU4aWNMdTdSdXRVTWlRSVducTBteVRTZVB0OWJoN2ZTV3hRQzRYdzhVQ1Rta1g1Q1B6N00zQTRJMjVQbkVMbjlqTmY2QUpYRXZlcU1LRGVid0Z5bXpDazhyTVd6c0FmQnFrVUo5TF9BQjBZZy12YTNGQVhpblRtRXc3ZGVST2k5Mlh6dVh3?oc=5","date":"2025-10-06","type":"trial","source":"statnews.com","summary":"Skye’s CB1-blocking obesity drug fails in mid-stage study - statnews.com","headline":"Skye’s CB1-blocking obesity drug fails in mid-stage study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNTFAtZ1JKQnlYOFJ5eElPZC1Ddy1iNFJhSHJuSHNydEJadzFpcThyLTdKMzRtMlRqVXYzVU9MS2E5T2xBNW5fbS03ZktsOW92Yi1zOWFjbFpjcnJDQjZpcENOVHMtSjFseld1M1MzbUtlaWFibDkwbEh2UTBreUxNblVpQjJZdER4TVh0b1Y5bGduaHlxaWlELXp1VGlTZw?oc=5","date":"2025-10-06","type":"trial","source":"MedCity News","summary":"Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment - MedCity News","headline":"Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wTEpYRUNNZFZBcWVEaDFPcEtBWVYzRkMwT0w3RjVIUVI1R0tUVlUzbkZ5aC05Rmg5ZDNIQWR4WXRYTE5iTE5nOVFmelk1elJLMTNV?oc=5","date":"2025-10-06","type":"trial","source":"firstwordpharma.com","summary":"Skye's obesity hopeful fails in mid-stage study - firstwordpharma.com","headline":"Skye's obesity hopeful fails in mid-stage study","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2025-07-24","type":"pipeline","source":"simplywall.st","summary":"After losing 27% in the past year, Skye Bioscience, Inc. (NASDAQ:SKYE) institutional owners must be relieved by the recent gain - simplywall.st","headline":"After losing 27% in the past year, Skye Bioscience, Inc. (NASDAQ:SKYE) institutional owners must be relieved by the rece","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNWmZEMmZHd19WRzlCb1docXRiQjNwMTJQWnY4dVVVbXU5VFJTYzRPeTl4RkJISDYzVDBWVUljeVcwaDNBdkROSlRWNlM1Q08zT0l6aDJwcWJHaUM4ZlVVVGZBZGpiUjZSZzR3X1VTc3k1cy1CbVFKVGc1RnM3aTVRRGlR?oc=5","date":"2025-05-23","type":"pipeline","source":"Yahoo Finance","summary":"3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Yahoo Finance","headline":"3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPMHc2Sko0SWhvaGdac214bTQ0UWVha2tzcnhIcjlzRUdQaVVva3JxWURKWlRHWG5sTmd1NWQwakR2YzNXSFYtQWNjOUhKWmxsN0pUTnJ5Q051OW1yZFdZNzFOU0NScXhFZGJfRkJDaWJ0OU9vZ2dvaE13RnRYSzZSV3lzVHloTUpVM2tzVzhMQS10VlFfMm1aeVgyQ3M3VnBLdEt5UGtTek9tZHM0WUlKZXc0VzJyREVGZmNxc2ZvbGZwWG9BeGw5N3AyTUlMQQ?oc=5","date":"2025-04-16","type":"pipeline","source":"Seeking Alpha","summary":"A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha","headline":"A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Allergan","Regeneron","Novartis"],"therapeuticFocus":["Obesity","Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6011805,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-55924814,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":28313633,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}